Accenture Beats Q4; FY27 Guide Still Does Not Clear a +10% Base

Summary: Accenture’s Q4 FY26 revenue was $18.68 billion, above its prior guide, and bookings grew 5% in local currency. But the new FY27 outlook is only 3%–6% local-currency revenue growth and 3%–6% adjusted-EPS growth; free-cash-flow guidance centers below FY26 actual. At the $183.37 pre-market reference, the FY27 midpoint implies about 12.6× EPS, while the probability-weighted 90-day sensitivity is negative and the adverse case exceeds 5%. Reject / no trade.

Published: Oct. 1, 2026, 7:46 p.m. Singapore time (UTC+08:00). The results were released before the U.S. open; quote time is shown separately.

Opportunity Ranking

This is a U.S.-only long screen. ACN is a material post-report update to the June 30 thesis, not a refreshed version of it: the old note relied on Q3 guidance and treated repurchases as a price floor; this screen tests FY26 actual conversion and FY27 guidance against the current reference price. The older six-to-twelve-month price horizon is not mature.

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Accenture (ACN)	Long	Q4 beat and improving bookings meet FY27 guidance of 3%–6% growth; the current quote implies 12.6× midpoint guided EPS, not an obvious discount to a +10% base	FY26 results released Oct. 1; official issuer earnings release	8:00 a.m. EDT call today; investor day Oct. 14; Q1 FY27 results, date unverified	Current short, options and fund positioning not verified	Reject: -0.5% modeled base, -30.2% historical downside stress, 0:1 favorable-base/adverse ratio	Pre-market mark only; no verified spread, depth or exit capacity	FY27 cash generation may be flat to down while investors assume continuing AI monetization and buybacks
2	Progress Software (PRGS)	Long	Q3 non-GAAP EPS beat its prior range and FY26 guidance rose, but ARR grew only 1%, NRR was 99%, and Domo added debt and integration risk	Sep. 30 issuer results and supplemental deck	Q4 FY26 results and Domo integration; formal FY27 guide expected in January	Current positioning not reviewed	Reject: near-term growth and acquisition debt do not establish a +10% base with bounded downside	No execution audit	Domo cash contribution and customer retention remain untested after close
3	Acuity (AYI)	Long	Q4 results were scheduled before the open, but an issuer Q4 release was not available in the source set by this run’s cutoff	Q4 call schedule is issuer-confirmed; latest accessible issuer results are Q3 from June 25	Oct. 1 results call scheduled for 8:00 a.m. EDT	Unknown	Insufficient fresh result evidence to support a responsible 10/5 map	No execution audit	Do not infer actual results from an estimate or an earnings calendar
4	SPDR S&P 500 ETF (SPY)	Long	Broad-market reference; no issuer-specific catalyst or idiosyncratic gap is established by this screen	Latest completed Sep. 30 session	Macro and index flows remain two-sided	Not reviewed	Reject: no supported +10% base / -5% adverse map	No live audit	Broad market risk can dominate the single-name result

Selected opportunity: ACN for the highest information value, not as the best executable opportunity.

Why this one now: Q4 actuals settle the June forecast test and expose a new FY27 cash-and-growth boundary. The release supports durable operations, but the guide does not support treating one strong quarter as a step-change in sustainable per-share growth.

What should surprise the reader: The headline 46% Q4 GAAP EPS increase is not the clean comparison. The prior-year quarter included $0.78 per share of business-optimization costs; against prior-year adjusted EPS of $3.03, this quarter’s $3.29 rose 9%. Adjusted operating margin improved only 20 basis points year over year. The FY27 free-cash-flow midpoint is about 1.9% below FY26 actual even as management expects revenue and adjusted EPS growth.

Why This Can Move More Than 5% Soon

The company-specific catalyst is the FY27 outlook, not the Q4 beat in isolation. Q4 revenue of $18.68 billion exceeded the $18.40 billion top of the prior range, but management’s next-year local-currency revenue guide is 3%–6%. A guide that later moves toward the low end, or evidence that bookings are not converting, could reopen the June valuation reset. Conversely, high-end growth, stable cash conversion and a higher multiple could support a re-rating. Neither path is established by the first pre-market mark.

The scale of the tail is observable, not hypothetical: on June 18, after Q3 results and a full-year guide reduction, ACN closed at $127.98 versus $156.01 the prior session. That is a historical event response, not a forecast of a repeat. It does establish that this equity can gap materially when growth expectations reset.

The Setup

Fact: Accenture’s issuer earnings release reports Q4 FY26 revenue of $18.679 billion, up 7% in local currency. New bookings were $22.17 billion, up 5% in local currency, with a 1.2 book-to-bill ratio. Full-year revenue rose 5% in local currency to $74.18 billion; FY26 bookings rose 3% in local currency to $84.54 billion with a 1.1 book-to-bill ratio.

Q4 reported GAAP operating margin was 15.3%, versus 11.6% GAAP and 15.1% adjusted in Q4 FY25. The adjusted comparison is more informative: only 20 basis points of expansion. GAAP diluted EPS was $3.29, 46% above prior-year GAAP EPS, but only 9% above the prior-year adjusted $3.03 after its $0.78 business-optimization cost. FY26 adjusted EPS was $13.97, up 8%.

Fact: FY27 guidance is 3%–6% revenue growth in local currency, $14.39–$14.81 GAAP diluted EPS, and $11.0–$11.8 billion free cash flow. Midpoints are $14.60 EPS and $11.40 billion FCF. FY26 FCF was $11.62 billion, so the midpoint implies roughly a 1.9% decline. FY27 capital-return guidance is at least $9.5 billion, against $11.0–$11.8 billion FCF guidance; capital return is a use of cash, not a floor under the share price.

Q4 FCF was $2.85 billion versus $3.81 billion in Q4 FY25; operating cash flow was $3.10 billion versus $3.91 billion, while DSO rose to 50 days from 47. The annual cash engine remains substantial, but the last quarter shows why annual FCF guidance and cash conversion matter more than the adjusted-EPS headline.

Check on the June 30 thesis

The prior June screen named three Q4 tests: new bookings below $17.5 billion, GAAP operating margin below 13.5%, and FY26 FCF below $10 billion. The reported results cleared all three: bookings were $22.17 billion, GAAP margin 15.3%, and FY26 FCF $11.62 billion. Those operating checkpoints are resolved favorably. The old 6–12-month price map remains open, and no executed position or return is documented; this is not a realized trade result.

The old note also equated the $7.5 billion FY26 repurchase/redemption amount with roughly 9.5% share shrink and a “floor.” The new release reports 39.9 million shares repurchased or redeemed, including 37.5 million in open-market purchases, and approximately 596 million shares outstanding at Aug. 31. FY26 weighted-average diluted shares were 617.5 million versus 632.4 million in FY25, a 2.4% decline. These are different denominator measures, so they do not permit an exact net-share attribution. They do show why a dollar authorization cannot be converted directly into a guaranteed per-share accretion or downside floor.

The Market Price

Observation	Value	Timestamp	Source / limitation
Last completed regular-session close before the release	$183.36	Sep. 30, 3:59:58 p.m. EDT	ChartExchange; $6.24 above Sep. 29 close, before Q4 results were published
Post-release pre-market reference	$183.37	Oct. 1, 7:23:47 a.m. EDT	MarketScreener/FactSet quote panel; one cent above prior regular close, but venue, trade size, spread and depth are not supplied
27-analyst mean target, secondary aggregator	$193.03	Displayed Oct. 1 pre-market	MarketScreener; about 5.3% above $183.37, target horizon and revision cutoff not shown

The pre-market figure is reference-only. The 3.53% change displayed beside ACN on some pages is the Sep. 30 regular-session gain versus Sep. 29, before this release; it is not the post-report return. The current quote feed does not establish a consolidated executable market or order-book conditions.

At $183.37, FY27 midpoint EPS of $14.60 implies about 12.56× forward GAAP EPS. The same price is 13.12× FY26 adjusted EPS of $13.97. Neither ratio alone proves undervaluation. The analyst mean target at +5.3% is a secondary cross-check, not a probability-weighted estimate or the Desk’s target.

The Mispricing

The disagreement is between a strong resolved quarter and only modest forward per-share growth. Q4 exceeded guidance, bookings accelerated to 5% local-currency growth, and the company delivered $11.62 billion FY26 FCF. The counterweight is the new FY27 guide: 3%–6% revenue growth, 3%–6% adjusted-EPS growth, and FCF midpoint below FY26 actual. At the current reference, the market’s forward multiple is approximately 12.6×.

The strongest long argument is that a 1.2 book-to-bill, 141 quarterly client bookings above $100 million, improved Q4 results across all three geographic markets, and a 10–30 basis-point adjusted-margin expansion forecast could prove conservative. The strongest alternative is that these are healthy but ordinary growth rates for a services business facing AI substitution, variable project timing and federal-budget exposure. The release does not quantify AI-specific revenue conversion or provide a quarterly FY27 path that would distinguish those stories today.

Inference: the current price does not obviously assume a collapse; it prices the guide around 12.6× midpoint EPS. A +10% base would require either materially higher earnings than the guide or a meaningful multiple expansion. The evidence establishes neither as the highest-probability outcome.

The Positioning

Unknown: current short interest, borrow utilization, options open interest, dealer exposure, institutional flows and forced positioning were not verified. The 3.53% Sep. 30 rise occurred before the result; it cannot be assigned to the Q4 release. The post-release pre-market mark is nearly unchanged from the prior close, but one quote without consolidated volume or order-book detail does not establish investor rejection or acceptance.

The Catalyst

FY26 Q4 actuals — resolved: revenue exceeded the previous guide’s upper bound, bookings rose 5% in local currency and the reported FY26 FCF was $11.62 billion.
FY27 guidance — issued, not demonstrated: 3%–6% local-currency revenue growth, $14.39–$14.81 GAAP EPS and $11.0–$11.8 billion FCF. First-quarter guidance is $18.95–$19.60 billion revenue, 2%–6% local-currency growth, and 15.9%–16.1% GAAP operating margin.
Management call — upcoming at publication: scheduled for 8:00 a.m. EDT Oct. 1. The test is whether management can reconcile the 3%–6% annual outlook, recent bookings, AI-related work, U.S. federal exposure and FCF midpoint. Do not attribute unreported commentary to the issuer.
Investor day — scheduled: Oct. 14. It may clarify the strategy and AI monetization, but no new economic outcome is yet verified.
Cheapest falsification: compare Q1 FY27 revenue, bookings, adjusted margin, DSO and FCF with the new guide. Bookings that do not convert, a guide cut, or FCF below the stated range would challenge the long case; a single beat does not make the downside bound safe.

The Payoff

This 90-day sensitivity runs through Dec. 31, 2026 and uses the $183.37 pre-market reference. The top and base are explicit EPS-times-multiple assumptions; the bottom is a previously observed post-Q3 close used as a stress, not a valuation target, price floor or loss cap. The probabilities are subjective, mutually exclusive scenario weights, not historical frequencies. The base receives the highest weight because FY27 guidance is the best available earnings anchor and its midpoint is nearly in line with the displayed FactSet EPS estimate. The top requires both upper-range EPS and a re-rating; the bottom requires another guidance shock similar to the prior one.

Scenario	Probability	Target / Level	Return from $183.37	Horizon	Conditions	Evidence Quality
Top Case	20%	$207.34	+13.1%	Through Dec. 31, 2026	FY27 EPS reaches $14.81 and the market pays 14×; new bookings convert and the Q4 growth rate proves durable	Low; modeled multiple and upper guide
Base Case	60%	$182.50	-0.5%	Through Dec. 31, 2026	FY27 EPS midpoint $14.60 at 12.5×, close to the current 12.56× implied multiple	Low; explicit valuation assumption
Bottom Case	20%	$127.98	-30.2%	Through Dec. 31, 2026	Retest the June 18 close after the Q3 guide reset if bookings, federal demand or FY27 conversion disappoint	Medium for historical level; low for recurrence
Invalidation	n/a	Operating evidence, not a stop	Not applicable	Q1 FY27 and investor day	FY27 guide is cut, bookings fail to convert, or FCF/cash conversion materially misses the published outlook	Medium; observable but unresolved

The top is $14.81 × 14.0; the base is $14.60 × 12.5. The bottom is the observed June 18 close of $127.98, not a claim that this level will repeat or contain the downside. A more conservative bottom based on $14.39 × 11.0 would be $158.29, still 13.7% below the pre-market reference.

Probability-weighted expected value: $176.56, or -3.7% gross versus $183.37 before spread, slippage, fees or other costs. Current market level and timestamp: $183.37, Oct. 1 at 7:23:47 a.m. EDT; pre-market reference only. Prior completed regular close: $183.36. Primary instrument: ACN ordinary shares, research only. 10/5 favorable base move: -0.5%; no positive base reward. The +13.1% top case is not the highest-probability outcome. 10/5 credible adverse move: 30.2% to the historical June 18 close stress; this is not a maximum-loss bound. 10/5 measurement basis: Reference-only; entry price is null. 10/5 status: Reject. The base is below +10%, the adverse stress exceeds 5%, and base/adverse reward-risk is 0:1 before costs. Confidence: Low.

Sensitivity: At $14.60 midpoint EPS, a +10% price return from $183.37 requires about 13.82× earnings, versus 12.56× implied by the current mark. A 13.5× multiple would produce about $197.10, only +7.5%. Even if the bottom were narrowed to $158.29, the downside would remain 13.7% and the modeled base would still be negative. No scenario proves a 5% adverse cap.

The Kill Shot

Strongest long case: the actual Q4 beat is supported by better-than-guided revenue, positive book-to-bill, year-over-year FCF growth and a FY27 margin-expansion outlook. FY27 EPS guidance allows mid-single-digit growth, while at least $9.5 billion of cash returns is planned.

Strongest counterparty argument: the headline Q4 GAAP EPS and margin comparisons benefit from prior-year optimization costs. On adjusted comparisons, EPS rose 9% and operating margin expanded only 20 basis points. The FY27 FCF midpoint is below FY26 actual. Bookings are future work, not revenue; buybacks do not guarantee a share-price floor.

Most fragile long assumption: AI-enabled bookings and large client awards will translate into revenue and operating cash at sufficient scale to outgrow the 3%–6% guide without increasing delivery costs or reducing billable work.

Why a directionally right thesis can still lose: results can meet guidance while the share falls if investors expect faster AI monetization, bookings convert slowly, foreign exchange or government exposure worsens, or the market de-rates the multiple. The June decline shows the gap risk when guidance changes.

What Would Prove This Wrong

Q1 FY27 revenue and margin meet the issued ranges, with bookings converting into reported revenue and stable FCF.
The Oct. 14 investor day supplies measurable AI-related revenue, margin and client-conversion data, rather than bookings or product claims alone.
Quarterly DSO, operating cash flow, capex and buyback/redemption counts reconcile to the FY27 cash-return plan.
Regular-session price acceptance after the earnings call persists relative to the S&P 500 and IT-services peers.

These observations would justify rebuilding the valuation and downside map; they do not promote this screen automatically.

Risk Audit

Guidance: FY27 EPS growth is 3%–6% on an adjusted basis, and full-year FCF guidance ($11.0B–$11.8B) is not above FY26 actual ($11.62B) at its midpoint.
Cash conversion: Q4 FCF fell to $2.85B from $3.81B year over year; DSO increased to 50 from 47 days. Annual FCF remains strong, but receivable timing needs monitoring.
Capital return: FY26 $7.5B of repurchases/redemptions was an actual cash use; FY27’s $9.5B+ is guidance, not a contractual bid or guaranteed per-share accretion.
AI and labor: AI may create new transformation work and reduce labor hours per project at the same time. The release does not quantify net revenue or margin contribution from AI.
Government and macro: federal demand, client spending, currency, wage costs and delayed project starts can move bookings and revenue across quarters.
Execution: the quote is pre-market; spread, depth, venue, volume quality and exit liquidity are not established. Price gaps can exceed the modeled bottom stress.
Positioning: current short, options, fund-flow and dealer data are unknown.

Best Trade Strategy

No trade. Do not initiate a long using the pre-market mark or a consensus target. Entry remains null and execution is blocked. Reassess only after regular-session acceptance and a new map with a highest-probability base above +10%, credible adverse move within -5%, at least 2:1 reward/adverse risk, positive probability-weighted value after costs and verified liquidity. Common shares are the simplest future research expression; an index fund dilutes the issuer-specific thesis, while options cannot be assessed without a verified live chain and maximum-loss analysis. No options, leverage, margin, market orders or price-floor language.

Sources

Source	Date / observation	Use
Accenture FY26 Q4 and full-year issuer earnings release	Oct. 1; FY ended Aug. 31	Results, adjusted reconciliations, cash flows, repurchases, outstanding shares, FY27/Q1 guide and dividend
Accenture Business Wire release copy	Oct. 1, 6:40 a.m. EDT	Release time and cross-check of headline results; same issuer release
Accenture Q3 FY26 SEC-hosted release	Jun. 18	Prior guide, Q3 context and the material old/new evidence boundary
Accenture Q4 call schedule and investor-relations home	Oct. 1 call; Oct. 14 investor day	Dated events; investor day timing
ACN regular-session history	Sep. 30, 3:59:58 p.m. EDT	Pre-report regular close, range and volume
ACN pre-market quote and analyst consensus	Oct. 1, 7:23:47 a.m. EDT page reference	$183.37 pre-market mark, FactSet EPS context and 27-analyst average target; secondary data with no execution depth
ACN June 2026 historical price sequence	Jun. 17–18	Prior $156.01 to $127.98 result-day stress; historical observation, not forecast
Progress Q3 FY26 issuer release and supplemental deck	Sep. 30	Candidate comparison: ARR, retention, Q3 guide, Domo funding and leverage
Acuity Q4 FY26 release schedule and latest accessible Q3 FY26 issuer results	Q4 scheduled Oct. 1; Q3 Jun. 25	Candidate comparison and evidence cutoff
June 30 Accenture long screen	Jun. 30	Prior thesis and now-resolved Q4 operating checkpoints; no executed return reported

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	4	Q4 beat and modest FY27 guide point in different directions; current multiple needs a growth re-rating for +10%
Evidence base	4	Fresh issuer earnings release and quote references; same-day regular-session acceptance and post-call detail unavailable
Positioning and flows	2	Actual FY26 repurchases are reported; current holder, short, options and dealer positioning are not
Catalyst path	4	Q4 resolved, call and investor day are dated, and Q1 guide delivery is measurable
Payoff architecture	2	Explicit model but negative weighted value, non-positive base, and historical downside stress >5%
Invalidation discipline	4	Revenue, margin, FCF, DSO and bookings conversion provide observable tests
Differentiated insight	4	Separates a GAAP comparison effect from adjusted growth and the repurchase amount from net share-count change
Client value	5	Updates the prior quarter’s actual checkpoints without presenting an unexecuted return as performance
Total	29/40	Reject / no-trade screen; failed 10/5 economics override the score

Bottom Line

Accenture cleared the June thesis’s Q4 operating checkpoints and delivered a strong result. That resolves the old near-term test, not the long-term return question. FY27 guidance centers on modest growth, the current quote implies 12.6× midpoint EPS, and our base is flat while a repeat of the prior result shock remains a credible stress. Reject; no long signal.

AI Illustration Prompt

A sober editorial scene of a consulting operations dashboard beside two ledgers: one marked “bookings / $22.17B” and the other “cash converted / FY27 FCF guide.” A clean order pipeline flows toward a city skyline, while a subtle second track shows delayed client projects and a thinning billable-hours meter. Muted indigo, warm gray and paper white; no stock chart arrows or implied price floor. Add a small, readable “The Mispricing Desk” watermark at the lower right.